DDInter458 DDInter1644
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central nervous system (CNS) involving demyelinating lesions in the optic nerve, spinal cord, brainstem, and cerebrum. Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased permeability of the blood-brain barrier, which allows for the passage of pro-inflammatory mediators into the CNS.[A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. Enspryng®, a satralizumab formulation developed by Chugai Pharmaceutical and Roche, is uniquely formulated with "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors occurs in a pH-dependent manner - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the plasma to act again. This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single drug molecules to interact with multiple endogenous IL-6 receptors prior to elimination. Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD. It received subsequent approvals in Switzerland and Japan, and was approved for use by the FDA in August 2020, becoming the 3rd treatment to receive FDA approval for NMOSD (after [eculizumab] in June 2019 and [inebilizumab] in June 2020).
Cyclosporine {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is bound by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Cyclosporine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Cyclosporine {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Cyclosporine {u} (Compound) upregulates {v} (Gene) PMAIP1
PMAIP1 {u} (Gene) is upregulated by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Cyclosporine {u} (Compound) downregulates {v} (Gene) RRM2
RRM2 {u} (Gene) is bound by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Satralizumab
Cyclosporine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Satralizumab
Cyclosporine {u} (Compound) upregulates {v} (Gene) FOXO3
FOXO3 {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Cyclosporine {u} (Compound) upregulates {v} (Gene) SESN1
SESN1 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Satralizumab
Cyclosporine {u} (Compound) downregulates {v} (Gene) PNP
PNP {u} (Gene) is upregulated by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Cyclosporine {u} (Compound) downregulates {v} (Gene) MYBL2
MYBL2 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Satralizumab
Cyclosporine (Compound) downregulates DCK (Gene) and DCK (Gene) is bound by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Cyclosporine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Cyclosporine (Compound) downregulates DCK (Gene) and DCK (Gene) is downregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Cyclosporine (Compound) upregulates PMAIP1 (Gene) and PMAIP1 (Gene) is upregulated by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Cyclosporine (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is bound by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Satralizumab
Cyclosporine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Satralizumab
Cyclosporine (Compound) upregulates FOXO3 (Gene) and FOXO3 (Gene) is downregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Cyclosporine (Compound) upregulates SESN1 (Gene) and SESN1 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Satralizumab
Cyclosporine (Compound) downregulates PNP (Gene) and PNP (Gene) is upregulated by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Cyclosporine (Compound) downregulates MYBL2 (Gene) and MYBL2 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Satralizumab